COVID-19: Colorectal cancer endoscopic surveillance in IBD
- PMID: 34119037
- PMCID: PMC8192092
- DOI: 10.1016/S2468-1253(21)00168-0
COVID-19: Colorectal cancer endoscopic surveillance in IBD
Erratum in
-
Correction to Lancet Gastroenterol Hepatol 2021; 6: 526-27.Lancet Gastroenterol Hepatol. 2022 Jan;7(1):e1. doi: 10.1016/S2468-1253(21)00425-8. Lancet Gastroenterol Hepatol. 2022. PMID: 34895508 Free PMC article. No abstract available.
Conflict of interest statement
SD has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Takeda and Dr Falk, and has SD received support for attending meetings or travel from AbbVie, Takeda, Dr Falk, and Janssen. IDRA has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda, Vifor, and Dr Falk. DRG declares no competing interests.
Comment on
-
Predicting endoscopic activity recovery in England after COVID-19: a national analysis.Lancet Gastroenterol Hepatol. 2021 May;6(5):381-390. doi: 10.1016/S2468-1253(21)00058-3. Epub 2021 Mar 11. Lancet Gastroenterol Hepatol. 2021. PMID: 33713606 Free PMC article.
References
-
- Nakarai A, Kato J, Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108:83–89. - PubMed
-
- Clark G, Strachan JA, Carey FA, et al. Transition to quantitative faecal immunochemical testing from guaiac faecal occult blood testing in a fully rolled-out population-based national bowel screening programme. Gut. 2021;70:106–113. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
